Akebia Therapeutics to Present at Piper Sandler Healthcare Conference


Werte in diesem Artikel
Aktien

1.24 EUR 0.03 EUR 2.62 %

CAMBRIDGE, Mass., Nov. 20, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28th at 10:30 a.m. EST

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)

The Piper Sandler Healthcare Conference will take place November 28November 30, 2023, in New York. 

A webcast of the fireside chat can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com for approximately 90 days following the conference. 

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
Mcarrasco@akebia.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-piper-sandler-healthcare-conference-301992889.html

SOURCE Akebia Therapeutics

Aktuelle Akebia Therapeutics Aktie News

Werbung

Akebia Therapeutics Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Akebia Therapeutics nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
DatumRatingAnalyst
06.08.19 Akebia Therapeutics Buy H.C. Wainwright & Co.
11.07.19 Akebia Therapeutics Buy H.C. Wainwright & Co.
10.08.18 Akebia Therapeutics Buy Needham & Company, LLC
06.06.18 Akebia Therapeutics Buy H.C. Wainwright & Co.
07.12.17 Akebia Therapeutics Buy BTIG Research